Q2 2025 IDEXX Laboratories Inc Earnings Call Transcript
Key Points
- IDEXX Laboratories Inc (IDXX) reported a strong financial performance with an 11% increase in revenue as reported and 9% organically.
- The company achieved a record quarter for premium instrument placements, including nearly 2,400 IDEXX inVue DX instruments.
- Operating profit grew by 14% on a comparable basis, benefiting from solid revenue growth and operating margin gains.
- IDEXX increased its full-year revenue outlook by $90 million at midpoint, reflecting strong Q2 performance and favorable foreign exchange impacts.
- The company reported a 17% growth in earnings per share (EPS) on a comparable basis, supported by high operating profit gains.
- CAG Diagnostic recurring revenue growth in Q2 was constrained by macroeconomic and sector headwinds, leading to a 2.5% decline in US same-store clinical visit growth levels.
- Global Rapid assay revenues declined 3% organically in Q2, impacted by customers shifting pancreatic lipase testing to the Catalyst instrument platform.
- US clinical visits declined 2.5% in the quarter, reflecting ongoing pressure on clinical visit levels.
- Operating expenses decreased 9% year-over-year, but this was primarily due to a favorable comparison to a prior year litigation expense.
- The company faces ongoing macroeconomic pressures, including inflationary impacts that continue to pressure clinical visits.
Good morning and welcome to the IDEXX Laboratories second quarter 2025 earnings conference call. As a reminder, todayâs conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer, Andrew Emerson, Chief Financial Officer, and John Ravis, Vice President, Investor Relations.
IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx.com.
During this call, we will be discussing certain financial measures, not prepared in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
